Price Reductions for 2013 Supplementary Cycle B
Summary of 1 December 2013 Price Reductions for 2013 Supplementary Cycle B by Drug / Manner of Administration / Weighted Average Percentage Reduction:
| Drug | MOA | Weighted Average Percentage Reduction |
|---|---|---|
| Anastrozole | Oral | 25.70% |
| Atorvastatin | Oral | 50.06% |
| Letrozole | Oral | 23.70% |
| Mycophenolic acid | Oral | 24.83% |
| Olanzapine | Oral | 44.69% |
| Quetiapine | Oral | 28.16% |
| Venlafaxine | Oral | 39.69% |
For further information about weighted average ex-manufacture price outcomes for each brand and confirmation of brands with no reductions, please see the legal determination on the ComLaw web site. Final prices applicable on 1 December 2013 will be available under the ‘Advance Notice of New Prices Resulting from EAPD Cycles’ link on this Web site from early November 2013.
An agreed process for responsible persons to raise any questions or concerns arising from an outcome mentioned above is set out in the Price Disclosure Dispute Resolution Administrative Process. The date for lodgement of disputes is Tuesday, 27 August 2013.